61 related articles for article (PubMed ID: 22127844)
1. Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure.
Kovacs G; Maier R; Aberer E; Brodmann M; Graninger W; Kqiku X; Scheidl S; Tröster N; Hesse C; Rubin L; Olschewski H
Arthritis Rheum; 2012 Apr; 64(4):1257-62. PubMed ID: 22127844
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and management of pulmonary hypertension in systemic sclerosis.
Sweiss NJ; Hushaw L; Thenappan T; Sawaqed R; Machado RF; Patel AR; Gomberg-Maitland M; Husain AN; Archer SL
Curr Rheumatol Rep; 2010 Feb; 12(1):8-18. PubMed ID: 20425528
[TBL] [Abstract][Full Text] [Related]
3. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era.
Williams MH; Das C; Handler CE; Akram MR; Davar J; Denton CP; Smith CJ; Black CM; Coghlan JG
Heart; 2006 Jul; 92(7):926-32. PubMed ID: 16339813
[TBL] [Abstract][Full Text] [Related]
4. Exercise pulmonary hypertension in patients with systemic sclerosis based on updated guidelines.
Kanazawa Y; Goda A; Mohri T; Takeuchi S; Takeuchi K; Kikuchi H; Inami T; Soejima K; Kohno T
Sci Rep; 2024 Jun; 14(1):13358. PubMed ID: 38858443
[TBL] [Abstract][Full Text] [Related]
5. Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study).
Pan Z; Marra AM; Benjamin N; Eichstaedt CA; Blank N; Bossone E; Cittadini A; Coghlan G; Denton CP; Distler O; Egenlauf B; Fischer C; Harutyunova S; Xanthouli P; Lorenz HM; Grünig E
Arthritis Res Ther; 2019 Oct; 21(1):217. PubMed ID: 31655622
[TBL] [Abstract][Full Text] [Related]
6. Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension.
Valerio CJ; Schreiber BE; Handler CE; Denton CP; Coghlan JG
Arthritis Rheum; 2013 Apr; 65(4):1074-84. PubMed ID: 23280155
[TBL] [Abstract][Full Text] [Related]
7. Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study.
Saggar R; Khanna D; Shapiro S; Furst DE; Maranian P; Clements P; Abtin F; Dua S; Belperio J; Saggar R
Arthritis Rheum; 2012 Dec; 64(12):4072-7. PubMed ID: 22777623
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension.
Assad TR; Maron BA; Robbins IM; Xu M; Huang S; Harrell FE; Farber-Eger EH; Wells QS; Choudhary G; Hemnes AR; Brittain EL
JAMA Cardiol; 2017 Dec; 2(12):1361-1368. PubMed ID: 29071338
[TBL] [Abstract][Full Text] [Related]
9. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
[TBL] [Abstract][Full Text] [Related]
10. Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.
Maron BA; Hess E; Maddox TM; Opotowsky AR; Tedford RJ; Lahm T; Joynt KE; Kass DJ; Stephens T; Stanislawski MA; Swenson ER; Goldstein RH; Leopold JA; Zamanian RT; Elwing JM; Plomondon ME; Grunwald GK; Barón AE; Rumsfeld JS; Choudhary G
Circulation; 2016 Mar; 133(13):1240-8. PubMed ID: 26873944
[TBL] [Abstract][Full Text] [Related]
11. Characterization of patients with borderline pulmonary arterial pressure.
Kovacs G; Avian A; Tscherner M; Foris V; Bachmaier G; Olschewski A; Olschewski H
Chest; 2014 Dec; 146(6):1486-1493. PubMed ID: 25451346
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary arterial hypertension with below threshold pulmonary vascular resistance.
Ratwatte S; Anderson J; Strange G; Corrigan C; Collins N; Celermajer DS; Dwyer N; Feenstra J; Keating D; Kotlyar E; Lavender M; Whitford H; Whyte K; Williams T; Wrobel JP; Keogh A; Lau EM;
Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32341105
[TBL] [Abstract][Full Text] [Related]
13. [Management of borderline pulmonary arterial hypertension associated with connective tissue diseases].
Yoshifuji H; Kinoshita H
Nihon Rinsho Meneki Gakkai Kaishi; 2014; 37(6):454-61. PubMed ID: 25748129
[TBL] [Abstract][Full Text] [Related]
14. Clinical course of COPD patients with exercise-induced elevation of pulmonary artery pressure or less severe pulmonary hypertension presenting with respiratory symptoms and the impact of bosentan intervention-prospective, single-center, randomized, parallel-group study.
Kashiwada T; Tanaka Y; Tanaka T; Okano T; Saito Y; Seike M; Hino M; Kimura H; Gemma A
BMC Pulm Med; 2024 Feb; 24(1):90. PubMed ID: 38368315
[TBL] [Abstract][Full Text] [Related]
15. Deep Learning for Detection of Exercise-Induced Pulmonary Hypertension Using Chest X-Ray Images.
Kusunose K; Hirata Y; Yamaguchi N; Kosaka Y; Tsuji T; Kotoku J; Sata M
Front Cardiovasc Med; 2022; 9():891703. PubMed ID: 35783826
[TBL] [Abstract][Full Text] [Related]
16. A review of exercise pulmonary hypertension in systemic sclerosis.
Shaikh F; Anklesaria Z; Shagroni T; Saggar R; Gargani L; Bossone E; Ryan M; Channick R; Saggar R
J Scleroderma Relat Disord; 2019 Oct; 4(3):225-237. PubMed ID: 35382504
[TBL] [Abstract][Full Text] [Related]
17. Potential role of exercise echocardiography and right heart catheterization in the detection of early pulmonary vascular disease in patients with systemic sclerosis.
Kovacs G; Olschewski H
J Scleroderma Relat Disord; 2019 Oct; 4(3):219-224. PubMed ID: 35382501
[TBL] [Abstract][Full Text] [Related]
18. Advances in the management of pulmonary arterial hypertension.
Deshwal H; Weinstein T; Sulica R
J Investig Med; 2021 Oct; 69(7):1270-1280. PubMed ID: 34580123
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary hypertension phenotypes in patients with systemic sclerosis.
Haque A; Kiely DG; Kovacs G; Thompson AAR; Condliffe R
Eur Respir Rev; 2021 Sep; 30(161):. PubMed ID: 34407977
[TBL] [Abstract][Full Text] [Related]
20. Effect of bosentan in pulmonary hypertension development in systemic sclerosis patients with digital ulcers.
Castellví I; Simeón CP; Sarmiento M; Casademont J; Corominas H; Fonollosa V
PLoS One; 2020; 15(12):e0243651. PubMed ID: 33301540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
